Doxribtimine
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Doxribtimine
- Molecular weight
- 242.23
- Structure (SMILES)
- Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O
- doxribtimine component of mt 1621 2 deoxythymidine
- Doxribtimine component of mt-1621 2'-deoxythymidine
- 1 2 deoxy β d erythro pentofuranosyl 5 methyl 2 4 1h 3h pyrimidinedione
- 1-(2-Deoxy-β-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
- 2 deoxythymidine
- 2'-deoxythymidine
- 2'deoxythymidine
- 2′-Deoxythymidine
- BYL719 as dispersible tablets (DT)
- byl719 as dispersible tablets dt
- Deferasirox dispersable tablet (DT)
- deoxyribothymidine
- Deoxyribothymidine
- doxribtimine
- Doxribtimine
- doxribtimine [INN]
- DOXRIBTIMINE [USAN]
- Doxribtimine [WHO-DD]
- doxribtimine inn
- doxribtimine usan
- doxribtimine who dd
- DT
- DT (one-dose booster)
- IMPURITY C [EP IMPURITY]
- impurity c ep impurity
- kygevvi component doxribtimine
- KYGEVVI COMPONENT DOXRIBTIMINE
And 34 more, listed on the interactive page.
- CAS registry numbers
- 50-89-5
- ChEMBL ID
- CHEMBL52609
- InChIKey
- IQFYYKKMVGJFEH-XLPZGREQSA-N
- PubChem compound IDs
- 5789
- RxNorm IDs (RxCUI)
- 1372538
- FDA ingredient codes (UNII)
- VC2W18DGKR
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- thymidine
- Type
- Metabolite
- Condition
- Peritoneal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002087
- Subject identifier
- D010534
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004355
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006486
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0012301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016684
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0017575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018177
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0044970
- Condition identifier
- MONDO_0044970
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0100342
- Highest recorded phase
- 2
Trial references
- NCT00005025
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 104.55
- Calculated partition coefficient (ALogP)
- -1.51
- Calculated partition coefficient (XLogP)
- -1.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 17
- Molecular formula
- C10H14N2O5
- Monoisotopic mass
- 242.09027155
- Natural product
- Yes
- 50474-350
- Recorded assays
- 573
- Active assays
- 40
- Confirmatory
- Other
Related records
Trials (16)
- A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
- A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- A RETROspective Study of Patients With TK2d
- A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)
- A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
- An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
- Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
- Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
- Doxecitine and Doxribtimine-Expanded Access
- GEN2 Directed Cancer Immunotherapy Trial
- Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
- Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
- Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
- Quantification of Human Adipogenesis
- Treatment of TK2 Deficiency With Thymidine and Deoxycytidine
In development for (4)
- Fallopian tube cancer Phase 2
- Mitochondrial DNA depletion syndrome, myopathic form Phase 2
- Ovarian cancer Phase 2
- Peritoneum cancer Phase 2
Other linked conditions (1)
- Mitochondrial disease